This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bioterrorism  • Alert me on articles by topic

JAMA. 2002;287:579.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2001;50:1142

Many persons who were exposed to inhalational anthrax in the recent bioterrorism-related anthrax attacks have or are concluding their 60-day course of antimicrobial prophylaxis. Some persons, especially those who were exposed to high levels of anthrax spores, might want to take additional precautions. The U.S. Department of Health and Human Services (DHHS) is providing two additional options beyond the 60-day anti-microbial prophylaxis course: an extended 40-day course of antimicrobial prophylaxis and investigational postexposure treatment with anthrax vaccine.

The three preventive options for persons with risks for inhalational anthrax are (1) 60 days of antimicrobial prophylaxis, accompanied by monitoring for illness; (2) 40 additional days of antimicrobial prophylaxis (intended to provide protection against the theoretical possibility that anthrax spores might cause illness up to 100 days after exposure) accompanied by monitoring for illness or adverse reactions; and (3) 40 additional days of anti-microbial prophylaxis plus 3 doses of anthrax . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Modeling the Logistics of Response to Anthrax Bioterrorism
Zaric et al.
Med Decis Making 2008;28:332-350.
ABSTRACT  

The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.
Braithwaite et al.
Med Decis Making 2006;26:182-193.
ABSTRACT